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BACKGROUND AND PURPOSE
It is well recognized that vasopressin modulates the neurogenic control of the circulation. Here, we report the central
mechanisms by which vasopressin modulates cardiovascular response to stress induced by immobilization.
EXPERIMENTAL APPROACH
Experiments were performed in conscious male Wistar rats equipped with radiotelemetric device for continuous measurement
of haemodynamic parameters: systolic and diastolic BP and heart rate (HR). The functioning of the spontaneous baro-receptor
reflex (BRR) was evaluated using the sequence method and the following parameters were evaluated: BRR sensitivity (BRS)
and BRR effectiveness index (BEI).
KEY RESULTS
Under baseline physiological conditions intracerebroventricular injection of 100 and 500 ng of selective non-peptide V1a or
V1b or V2 receptor antagonist did not modify BP, HR and BRR. Rats exposed to 15 min long stress by immobilization
exhibited increase of BP, HR, reduction of BRS and no change in BEI. Pretreatment of rats with V1a receptor antagonist
did not modulate the BP, HR, BRS and BEI response to stress. Pretreatment of rats with V1b receptor and V2 receptor
antagonist, at both doses, prevented BRR desensitization and tachycardia, but failed to modulate stress-induced
hypertension.
CONCLUSIONS AND IMPLICATIONS
Vasopressin by the stimulation of central V1b- and V2-like receptors mediates stress-induced tachycardia and BRR
desensitization. If these mechanisms are involved, BRR desensitization in heart failure and hypertension associated with poor
outcome, they could be considered as novel targets for cardiovascular drug development.
Abbreviations
BEI, baro-receptor reflex effectiveness index; BNST, bed nucleus of the stria terminalis; BRR, baro-receptor reflex; BRS,
baro-receptor reflex sensitivity; DBP, diastolic BP; HR, heart rate; IML, intermediolateral column of the spinal cord;
MBP, mean BP; NTS, nucleus of the solitary tract; PAG, periaqueductal grey matter; PI, pulse interval; PVN,
paraventricular nucleus; RVLM, rostoventrolateral medulla; SBP, systolic BP
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Introduction
The baro-receptor reflex (BRR) is the major corrector of arte-
rial BP. Its malfunction has been associated with increased BP
variability and the poor outcome of cardiovascular disease
such as hypertension and congestive heart failure (Mortara
et al., 1997; Narkiewicz and Grassi, 2008). Many neurohu-
moural factors have been found to regulate the function of
the BRR, and vasopressin is among the key ones.
The major sources of vasopressin are the paraventricular
nucleus (PVN) and the supraoptic nucleus of the hypothala-
mus. The magnocellular part of the PVN that projects to the
neurohypophysis releases vasopressin in the circulation
where it acts as an antidiuretic hormone and vasoconstrictor
agent in most vascular beds (Burbach et al., 2001; Murphy
et al., 2012). Peripherally released vasopressin also sensitizes
the BBR via the area postrema, a circumventricular organ
devoid of blood–brain barrier, to decrease cardiac output and
limit the increase in BP associated with the augmentation of
the peripheral resistance (Hasser and Bishop, 1990). Vaso-
pressin also acts in the brain as neurotransmitter/modulator
in cardiovascular control. Neurons from the parvocellular
part of the PVN project to the nucleus of the solitary tract
(NTS), where BRR afferents terminate, the rostral part of the
ventrolateral medulla (RVLM) and the intermediolateral
column of the spinal cord (IML) to modulate tonic sympa-
thetic outflow to the heart, blood vessels and the kidneys
(Pyner, 2009; Chen and Toney, 2010).
We hypothesized that centrally released vasopressin
might be involved in the modulation of the BRR modulation
under physiological conditions, baseline and/or stress. A
number of studies indicate that vasopressin receptors are
widely distributed in the brain neuronal network involved in
cardiovascular control (Brinton et al., 1984; Ostrowski et al.,
1994; Hernando et al., 2001; Vargas et al., 2009; Sato et al.,
2011). Because vasopressin produces its effects by the stimu-
lation of three distinct G–protein-linked membrane recep-
tors, we injected selective and non-peptide V1a, V1b, V2
vasopressin antagonists in the lateral ventricle of freely
moving adult male Wistar rats both under baseline condi-
tions and during exposure to stress, when vasopressin release
is enhanced (Carrasco and Van de Kar, 2003). The major
strengths of this study are the use of highly selective non-
peptide vasopressin V1a, V1b and V2 receptor antagonists,
without agonist properties, as well as the sequence method-
ology for the evaluation of the spontaneous BRR that circum-
vents the use of vasoactive drugs, that by itself interfere with
BRR functioning.
Methods
All experimental procedures in this study conformed to Euro-
pean Communities Council Directive of November 24, 1986
(86/609/EEC). The experimental protocol was approved by
the School of Medicine, University of Belgrade, ethics review
board (approval reference number 6R/2010).
Animals
Experiments were performed in male, 12-week-old Wistar rats
bred at a local animal facility, weighing 310–360 g. Rats were
housed individually in a controlled environment: 12 h/12 h
light–dark cycle, temperature 21°C  2 and humidity 65%
 9, with access to standard food pellets (0.2 % sodium
content, Veterinarski zavod Subotica, Serbia) and tap water
ad libitum. The number of rats in each protocol was calcu-
lated statistically taking into account intra-group variability,
using software ‘Power Sample Size Calculation’ available at:
http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/Power
SampleSize, for power of 90% and type I error probability of
0.05. At the end of the experiment, the rats were euthanized
by an overdose of thiopentone sodium (150 mg, i.p.).
Surgery
Rats underwent two surgical procedures at 10 days intervals.
Under combined ketamine (100 mg·kg-1, i.m.) and xylazine
(10 mg·kg-1, i.m.) anaesthesia, a 3 cm long medial abdominal
incision was made and the intestine retracted to expose the
abdominal aorta. The tip of the catheter of the radio telemet-
ric probe (TA11-PA C40, DSI, Transoma Medical, St. Paul, MN,
USA) was inserted into the aorta using a 21 G needle. The
inserted catheter was fixed with 3 M VetbondTM and tissue
cellulose patch (DSI, Transoma Medical). The transmitter was
attached to the anterior abdominal wall and the wound was
closed by suture. To prevent bacterial infection, neomycin
and bacitracin were sprayed topically, and the rats were
treated with gentamicin (25 mg·kg-1 i.m.) 3 days previous,
and on the day of surgery. To reduce pain, rats received
metamizole (200 mg·kg-1·day-1, i.m.) on the day of surgery
and for the next 2 days. Each rat was housed in a Plexiglas
cage (30 ¥ 30 ¥ 30 cm) and left to recover fully for 10 days
prior to the second surgery.
A second surgery was performed under the same anaesthe-
sia. Each rat’s head was mounted in the stereotaxic frame and
the skin was incised 1 mm to expose the skull. The stereotaxic
coordinates were derived from Paxinos and Watson (2005).
The guide cannula (G22) protruded in the lateral ventricle
4 mm beneath the skull and was positioned anterior-posterior
= 1.08 mm (from bregma) and lateral = 1.5 mm (from
midline), and fixed with dental cement. The skin above
was sutured and sprayed with antibiotics (neomycin and
bacytracin), and the guide was plugged with a stainless-steel
pin. In the post-operative period, rats were treated with gen-
tamicin (25 mg·kg-1 i.m.) and metamizole (200 mg·kg-1·day-1,
i.m.) 1 day before and 3 days after surgery. Five days elapsed
before rats were exposed to experimentation.
Pilot experiments
To define the selective dose of vasopressin antagonists, we
used previous experience (Milutinovic´ et al., 2006). The car-
diovascular effect of vasopressin administered in a dose of
50 ng·5 mL–1 (i.c.v.) to conscious rats was assessed without and
with pretreatment of rats (n = 6) with 100 ng and 500 ng of
V1a or V1b or V2 receptor antagonists at 2 days intervals
(wash-out period).
Experimental design
All experiments started at 10:00 h in a quiet surrounding
under controlled environmental conditions, following
60 min long baseline recordings. Cardiovascular parameters
and arterial BRR were evaluated under baseline physiological
conditions and during exposure to stress induced by 15 min
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long immobilization period under opaque Plexiglas restrainer
(6 cm in width by 4 cm in height). A group of rats (n = 6) was
treated with 5 mL of vehicle (i.c.v.), 100 ng/5 mL (i.c.v.) and
500 ng/5 mL (i.c.v.) of vasopressin antagonist (V1a or V1b or
V2 receptor antagonist) at 2 h intervals. A period of 2 days
elapsed between different drug administrations. Another
group of six rats was injected with three consecutive injec-
tions of vehicle 5 mL (i.c.v.) of 0.9% NaCl or 5% dimethyl
sulfoxide (DMSO) or 10% DMSO respecting the same time-
line for drugs. This experimental group was introduced to
eliminate effects of volume or vehicle on cardiovascular
parameters. Each injection of drug or vehicle was followed by
30 min long recording periods of arterial BP.
In the stress protocol, 36 rats were randomized in six
experimental groups: V1a-100, V1a-500, V1b-100, V1b-500,
V2-100 and V2-500. Rats were first recorded 15 min for base-
line BP, then a vehicle or drug was injected i.c.v. followed by
15 min long recordings of BP. This was followed by 15 min
long immobilizations during which BP was also recorded.
Cardiovascular signal processing and analysis
Arterial BP was digitalized at 1000 Hz in Dataquest A.R.T. 4.0
software, (DSI, Transoma Medical). Systolic BP (SBP) and
diastolic BP (DBP) and pulse interval (PI) or its inverse, heart
rate (HR), were derived from the arterial pulse pressure as
maximum, minimum and inter-beat interval of the pulse
pressure wave, respectively. Mean BP (MBP) was calculated as
the integral of the arterial pulse pressure wave. For each
registration period mean value of SBP, MBP, DBP, HR and PI
was calculated, and again averaged  SEM for the whole
experimental group (shown in tables and graphs).
Evaluation of the spontaneous BRR by
the method of sequences
The method is explained in detail elsewhere (Bajic´ et al.,
2010). Briefly, a spontaneous BRR sequence is a stream of
consecutively increasing/decreasing SBP samples, followed by
a stream of increasing/decreasing PI interval samples delayed
by three, four or five beats in respect to SBP. A threshold for
sequence length was set to four beats (Loncˇar-Turukalo et al.,
2011). The following BRR features were evaluated
• BRR sensitivity (BRS, ms·mmHg–1) assessed as a linear regres-
sion coefficient averaged over all identified sequences
(pulse interval = BRS·SBP + const, where fitting of the curve
is done in a least square sense);
• BRR effectiveness index (BEI) calculated as the ratio of
number of sequences versus number of SBP ramps.
Drugs
Nonpeptide and selective V1a (SR49059), V1b (SSR149415)
and V2 (SR121463) antagonists were kindly donated by Dr.
Claudine Serradeil-Le Gal from Exploratory Research Depart-
ment of Sanofy-Synthélabo Recherche (Toulouse, France).
[Arg8]-vasopressin acetate was purchased from Sigma-Aldrich
(Munich, Germany) and neomycin bacitracin spray from
Galenika (Belgrade, Serbia). Ketamine, xylazine and thiopen-
tal sodium injections were purchased from Marlo Farma (Bel-
grade, Serbia). Metamizol sodium and gentamicin injections
were purchased from Hemofarm (Vrsac, Serbia).
Vasopressin [(Arg8)-vasopressin acetate] and the V2
antagonist (SR121463) were dissolved in pyrogen-free saline
while the V1a antagonist (SR49059) and V1b antagonist
(SSR149415) were dissolved in 10% (vol/vol) and 5% (vol/vol)
DMSO, respectively.
Statistics
Cardiovascular parameters are presented as mean  SEM.
Differences between experimental protocols were analysed by
two-way ANOVA for repeated measures followed by post hoc
Bonferroni test using GraphPad Prism 4 software (GraphPad
Software Inc., San Diego, CA, USA). Statistical significance
was considered at P < 0.05.
Results
Pilot studies
Vasopressin injected at a dose of 50 ng (i.c.v.) induced a
consistent and significant increase in BP that lasted up to
20 min: SBP increased by 17.5 mmHg  4.3, P < 0.01, and
DBP by 8 mmHg  2.2, P < 0.05. Vasopressin did not affect
HR significantly. The hypertensive effect of vasopressin was
inhibited by pretreatment of rats by100 ng (i.c.v.) of the V1a
antagonist (SBP increased only by 1.6 mmHg  5.7, P > 0.05,
and DBP by 1 mmHg 2.3, P > 0.05), and by 500 ng (i.c.v.) of
the V1a antagonist (SBP increased by 2.5 mmHg  8.3, P >
0.05, and DBP by 1.8 mmHg  2.9 P > 0.05). V1b antagonist
pretreatment by 100 ng (i.c.v.) did not prevent the significant
rise of SBP induced by vasopressin (21 mmHg  5.7, P < 0.05)
while DBP did not change significantly (9.8 mmHg  4.6).
V1b antagonist pretreatment in a dose of 500 ng (i.c.v.) fol-
lowed by 50 ng (i.c.v) of vasopressin decreased SBP by
0.5 mmHg  3.7 (P > 0.05) and DBP increased by 3.8 mmHg
 3.4 (P > 0.05). Rats pretreated with 100 ng (i.c.v.) and
500 ng (i.c.v.) of the V2 antagonist exhibited hypertension
following vasopressin injection (50 ng, i.c.v.). SBP and DBP
increased, respectively by 19.9 mmHg 3.8 (P < 0.05), and by
9.2 mmHg  3.1 (P < 0.05) for 100 ng of V2 antagonist
pretreatment and 19.9 mmHg  3.3 (P < 0.01), and
7.8 mmHg  1.1 (P < 0.05) for 500 ng of V2 antagonist
pretreatment. Based on these studies, we used both 100 and
500 ng doses to ascertain functional separation between the
effects of V1a, V1b and V2 receptor antagonists.
Effects of non-peptide vasopressin antagonists
on BP, HR and BRR under baseline
physiological conditions
Table 1 shows that under baseline physiological conditions,
V1a, V1b and V2 antagonists applied i.c.v. in a dose of 100
and 500 ng did not change the mean values of SBP, MBP, DBP
and HR and did not modulate BRS (Table 1). BEI was also
unaffected by drug treatment (Figure 1).
Effects of immobilization on BP, HR and BRR
Exposure of rats to 15 min long immobilizations increased
SBP, MBP, DBP and HR (Tables 2–4). This was associated with
a decrease in BRS (Figure 2), while BEI remained unchanged
(Figure 3).
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Effects of immobilization on BP, HR and BRR
under vasopressin receptor blockade
The V1a antagonist applied i.c.v. to conscious rats in a dose
of 100 and 500 ng did not modify the effect of stress on
SBP, MBP, DBP, HR, BRS (Table 2) and BEI (Figure 3, upper
panel).
Rats pretreated with 100 and 500 ng (i.c.v.) of the V1b
antagonist and exposed to immobilization exhibited compa-
rable increase of SBP, MBP and DBP with non-treated rats
(Table 3). However, V1b antagonist at both doses blunted
the HR response to stress, prevented BRS desensitization
(Table 3), and only at 500 ng increased BEI (Figure 3, middle
panel).
V2 antagonist pretreated rats exposed to stress exhibited a
comparable increase of SBP, MBP and DBP to non-treated rats,
at both doses. However, the stress-induced tachycardia and
BRS desensitization were inhibited (Table 4) while BEI was
not modified by treatment (Figure 3, lower panel).
Discussion and conclusions
The present study in conscious rats shows that, under basal
physiological conditions, central vasopressin does not
modulate BP, HR and baro-receptor control of the circula-
tion, whereas during exposure to stress induced by im-
mobilization, vasopressin mediates HR increase and BRR
desensitization by the stimulation of central V1b- and
V2-like receptors.
Our experiments also show that, under basal physiologi-
cal conditions, centrally acting vasopressin does not partici-
pate in BP maintenance. This finding is in line with those of
Imai and co-workers (1990), who reported that i.c.v. injected
desmopressin, a selective V2 agonist or i.c.v. injected selec-
tive V1 antagonist do not affect BP and HR of rats under
basal physiological conditions. They also found that BP and
HR of rats with hereditary diabetes insipidus (DI) under
basal conditions are similar to Long-Evans rats, a parent rat
strain without DI. However, it was recently reported that
V1a receptor knockout mice exhibit lower BP levels in com-
parison to wild-type controls and that this hypotension is
due to the lack of peripheral V1a receptors resulting in
attenuation of RAS functioning and BRS (Fujiwara et al.,
2012). In DI rats, both the decrease in BRS (Imai et al., 1983)
and no change in BRS (Gardiner and Bennett, 1988) have
been reported. Nonetheless, electrical stimulation of PVN
(Ciriello and Caralesu, 1980) as well as microinjection of
vasopressin in NTS (Matsuguchi et al., 1982; Michelini and
Bonagamba, 1988; Kubo and Kihara, 1990; Hegarty and
Felder, 1995) have been found to produce baro-reflex desen-
sitization and tachycardia. On the other hand, injection of
vasopressin into the area postrema (Hasser and Bishop,
1990) [note that the area postrema can be reached by drugs
injected via both sides of the blood–brain barrier] was found
to enhance BRS (Unger et al., 1986; Brizzee and Walker,
1990). Therefore, we cannot entirely rule out a possibility
that i.c.v. injected drugs in our experiments may have acted
at multiple sites to produce concomitantly opposing effects
on the BRR.
Table 1
Effects of V1a, V1b and V2 receptor antagonist on SBP, MBP, DBP, HR and BRS under baseline physiological conditions
I.C.V.
SBP
(mmHg)
MBP
(mmHg)
DBP
(mmHg)
HR
(bpm)
BRS
(ms·mmHg-1)
10% DMSO (5 mL) 120  6 93  4 80  2 377  19 1.4  0.2
V1a (100 ng·5 mL-1) 123  5 94  3 79  3 386  22 1.3  0.3
V1a (500 ng·5 mL-1) 122  4 94  4 80  2 390  20 1.2  0.2
5% DMSO (5 mL) 126  3 96  4 81  3 373  18 1.1  0.2
V1b (100 ng·5 mL-1) 122  4 95  4 81  4 371  19 1.4  0.4
V1b (500 ng·5 mL-1) 121  3 93  5 79  2 371  22 1.4  0.2
0.9% NaCl (5 mL) 123  3 96  3 83  3 398  17 1.2  0.1
V2 (100 ng·5 mL-1) 124  6 96  4 82  3 394  23 1.1  0.2
V2 (500 ng·5 mL-1) 125  3 96  3 82  6 383  17 1.1  0.2
Values are mean  SEM of six experiments. In this and the following tables, V1a, V1a-receptor antagonist; V1b, V1b-receptor antagonist; V2,
V2-receptor antagonist.
Figure 1
Effects of vasopressin V1a, V1b and V2 receptor antagonist on BEI
under baseline physiological conditions. Values are mean  SEM of
six experiments.
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In the present experiments, immobilization of rats
induced a typical haemodynamic defence with instantaneous
BP and HR increase, and a reduction of BRS, as part of a
complex neuroendocrine response to stress. Injection of vaso-
pressin antagonists previous to exposure to stress modified
the cardiovascular response. Particularly, the V1b receptor
antagonist prevented the stress-induced HR increase and BRS
desensitization. An interesting finding is that a V2 receptor
antagonist also efficiently prevented BRR desensitization.
Although this study cannot pinpoint the exact brain struc-
ture where vasopressin V1b and V2 receptors are stimulated
during stress, the injection site of antagonists in the lateral
cerebral ventricle of the rat points towards adjacent brain
structures bed nucleus of the stria terminalis (BNST), PVN and
periaqueductal grey matter (PAG), all of which are well
known to play an important role in cardiovascular regulation
and related neuroendocrine functions (Loewy and McKellar,
1980). This view is further supported by the morphological
finding of vasopressin receptors in BNST, PVN and PAG of
the rat brain (Brinton et al., 1984; Ostrowski et al., 1994;
Hernando et al., 2001; Yang et al., 2006; 2007; Vargas et al.,
2009).
V1b receptors found in BNST have been found to contrib-
ute crucially to the emotional response to stress (Griebel
et al., 2002), and strong emotions can increase BP and HR.
BNST is abundantly interconnected with the hypothalamus,
Table 2
Effects of stress on SBP, MBP, DBP, HR and BRS in rats pretreated with V1a-receptor antagonist or vehicle (10% DMSO)
I.C.V.
SBP
(mmHg)
MBP
(mmHg)
DBP
(mmHg)
HR
(bpm)
BRS
(ms·mmHg-1)
BASELINE
10% DMSO (5 mL)
123  4 96  4 83  4 390  16 1.4  0.2
STRESS
10% DMSO (5 mL)
+20  4** +22  4** +23  5** +55  12* 0.66  0.2 *
BASELINE
V1a (100 ng·5 mL-1)
120  4 96  3 84  3 370  10 1.4  0.3
STRESS
V1a (100 ng·5 mL-1)
+15  3** +16  3** +16  3** +59  19* 0.75  0.1 *
BASELINE
V1a (500 ng·5 mL-1)
120  5 95  4 82  3 395  13 1.8  0.3
STRESS
V1a (500 ng·5 mL-1)
+12  1* +10  5* +9  2* 50  22 * 1.1  0.4*
Values are mean  SEM of six experiments. Stress increases SBP, MBP, DBP, HR and decreases BRS. Note that V1a antagonist pretreatment
does not modify the stress response. *P < 0.05, **P < 0.01 versus corresponding baseline.
Table 3
Effects of stress on SBP, MBP, DBP, HR and BRS in rats pretreated with V1b receptor antagonist or vehicle (5% DMSO)
I.C.V.
SBP
(mmHg)
MBP
(mmHg)
DBP
(mmHg)
HR
(bpm)
BRS
(ms·mmHg-1)
BASELINE
5% DMSO (5 mL)
123  4 96  4 83  4 390  16 1.4  0.2
STRESS
5% DMSO (5 mL)
+21  4** +22  4** +24  5** +55  12* 0.65  0.2*
BASELINE
V1b (100 ng·5 mL-1)
123  3 95  4 81  5 400  17 1.2  0.1
STRESS
V1b (100 ng·5 mL-1)
+19  2** +10  1* +9  2* +17  10 1.3  0.3
BASELINE
V1b (500 ng·5 mL-1)
121  7 98  5 87  4 382  8 1.3  0.2
STRESS
V1b (500 ng·5 mL-1)
+17  6** +10  3* +6  2 +26  20 1.2  0.3
Values are mean  SEM of six experiments. V1b antagonist, at both doses, decreases stress-induced tachycardia and BRR desensitization.
*P < 0.05, **P < 0.01 versus corresponding baseline.
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PAG and brainstem vagal nuclear complex (Berk and
Finkelstein, 1981; Ter Horst and Luiten, 1986; Thompson
et al., 1996) and they act collectively to mediate integrated
fear response (Walker et al., 2003). Microinjections of the V1b
antagonist in the BNST were found to exert anxiolytic and
antidepressant effects (Griebel et al., 2002). We reported
previously that centrally applied V1b antagonist reduces
sympatho-respiratory response of rats exposed to stress and
shortens the recovery of BP and HR (Milutinovic´ et al., 2006;
Stojicˇic´ et al., 2006; 2008). In the present experiments, V1b
antagonist was most effective in reducing HR increase
induced by immobilization and prevented BRR desensitiza-
tion. Our findings complement those of Roper and
co-workers (2010) who demonstrate that V1b knock-out mice
exhibit reduced blood ACTH and corticosterone response to
stress.
Another possible site of action of V1b receptor antagonist
in our experiments is within the PVN, a major integrative site
of neuro-endocrine and behavioural response to stress. Mor-
phological studies indicate abundance of V1a and V1b vaso-
pressin and oxytocin receptors on somata and dendrites of
magnocellular neurons in the PVN (Ostrowski et al., 1994;
Hernando et al., 2001). The role of these receptors is not yet
elucidated. It has been suggested that they could have a role
in the paracrine and autocrine regulation of magnocellular
neurons (Tobin et al., 2012). Using specific antisense oligom-
ers directed against oxytocin mRNA in the PVN of rats, evi-
dence was provided that oxytocin-containing neurons that
project to the brainstem are critical for the HR response to
shaker stress (Morris et al., 1995). Microdialysis studies con-
firmed that, during exposure to stress, there is an increase in
oxytocin content in the PVN (Morris et al., 1995; Nishioka
Table 4
Effects of stress on SBP, MBP, DBP, HR and BRS in rats pretreated with V2-receptor antagonist or vehicle (0.9% NaCl)
I.C.V.
SBP
(mmHg)
MBP
(mmHg)
DBP
(mmHg)
HR
(bpm)
BRS
(ms·mmHg-1)
BASELINE
0.9% NaCl (5 mL)
123  4 96  4 83  4 392  16 1.3  0.2
STRESS
0.9% NaCl (5 mL)
+22  4** +23  4** +26  5** +58  12* 0.59  0.2*
BASELINE
V2 (100 ng·5 mL-1)
125  3 100  4 87  5 392  17 1.1  0.1
STRESS
V2 (100 ng·5 mL-1)
+16  7** +14  4** +13  3** +24  23 1.3  0.7
BASELINE
V2 (500 ng·5 mL-1)
124  1 98  4 85  1 380  5 1.3  0.2
STRESS
V2 (500 ng·5 mL-1)
+16  4** +18  2** +21  3** +26  17 1.0  0.3
Values are mean  SEM of six experiments. V2 antagonist pretreatment, at both doses, reduces stress-induced HR increase and prevents BRR
desensitization. *P < 0.05, **P < 0.01 versus corresponding baseline.
Figure 2
Effects of stress by immobilization on the BRS in one conscious rat. Note a decrease of BRS by stress (BRS, line slope).
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et al., 1998). Callahan and co-workers have shown that elec-
trolytic (Callahan et al. 1989) and chemical (Callahan et al.
1992) lesions of PVN, as well as central administration of only
oxytocin antagonist, prevents stress-induced tachycardia.
They also showed that DI rats that lack vasopressin, but not
oxytocin, exhibit normal HR response to foot-shock. Their
results altogether suggest that PVN-derived oxytocin, not
vasopressin, mediates stress-induced tachycardia. This is in
line with present report that V1a antagonist failed to prevent
stress-induced tachycardia. It also does not support a role of
V1b receptors in PVN in stress-induced BRR desenzitization.
The effects of V2 receptor antagonism are intriguing.
Pharmacological experimentation supports the existence of
V2 receptors in adult rat brain (Imai et al., 1990; Sampey
et al., 1999; Yang et al., 2006; 2007). Recent studies using V2
antagonists and small interfering RNA gene knock-down
technology suggest that V2 receptors in PVN and PAG might
be involved in anti-nociception (Yang et al., 2006) and noci-
ception (Yang et al., 2007), respectively. Morphological
studies indicate that PVN has abundant connections with the
defence area in the PAG (Swanson and Kuypers, 1980;
Geerling et al., 2010) and that PAG neuronal projections to
the medulla are involved in stress-induced tachycardia and
BRR inhibition (Dean and Coote, 1986; Farkas et al., 1998; De
Menezes et al., 2009; Netzer et al., 2011). Therefore, it is pos-
sible that V2-like receptors in PAG are involved in the stress-
induced BRR desensitization, in our experiments.
It can be concluded that, in conscious rats, central vaso-
pressin V1b and V2 receptors mediate stress-induced BRR
desensitization enabling concurrent BP and HR increase. If
V1b and V2-like central receptors are involved in BRR desen-
sitization in heart failure and hypertension associated with
poor outcome, our findings could open new perspectives in
the treatment of these neurocardiogenic deregulations.
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